Skyepharma PLC Announces Research Update

Press Release Source: Skyepharma PLC Skyepharma PLC Announces Research Update On Tuesday June 9, 2009, 10:14 am EDT LONDON--(MARKET WIRE)--Jun 9, 2009 --   SKYEPHARMA PLC - FlutiformTM U.S. Filing Update SkyePharma PLC (LSE:SKP.L) recently announces that the US Food and Drug Administration (FDA) has issued a communication in respect of the New Drug Application (NDA) for its lead development product, FlutiformTM (fluticasone propionate/formoterol fumarate), an investigational treatment for persistent asthma in patients 12 years of age and older. The communication,
Read article...

SkyePharma PLC: Flutiform NDA Accepted for Review

Read article...

Skyepharma PLC announces Board Appointment

Press Release Source: Skyepharma PLC Skyepharma PLC announces Board Appointment On Friday May 15, 2009, 2:03 am EDT London, UK--(MARKET WIRE)--May 15, 2009 --   Appointment of New Non-Executive Director LONDON, UK, 15 May, 2009 - SkyePharma PLC (LSE:SKP.L) recently announces that it will appoint a new Non-Executive Director, Dr Thomas Werner, to the Board with effect from 16 May 2009. Dr Werner, 52, is a senior-level pharmaceutical executive with over 26 years experience in the pharmaceutical industry, most recently as Managing Director and Senior Vice-Pr
Read article...

Skyepharma Announces Interim Management Statement

Press Release Source: Skyepharma PLC Skyepharma Announces Interim Management Statement On Friday May 15, 2009, 2:00 am EDT LONDON--(MARKET WIRE)--May 15, 2009 --   SKYEPHARMA PLC - INTERIM MANAGEMENT STATEMENT LONDON, UK, 15 May 2009 - Ahead of its Annual General Meeting later recently , SkyePharma PLC (LSE:SKP.L) publishes its Interim Management Statement. This provides an update on key matters since the preliminary announcement of annual results issued on 26 March 2009. Trading The Company has made good progress in the first few months of the year, including the s
Read article...